TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · IEX Real-Time Price · USD
6.92
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
7.00
+0.08 (1.16%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
TScan Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 11.4, with a low estimate of 9.00 and a high estimate of 15. The average target predicts an increase of 64.74% from the current stock price of 6.92.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 4, 2024.
Analyst Ratings
The average analyst rating for TCRX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 3 | 3 | 3 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +116.76% | Jun 4, 2024 |
| BTIG | BTIG | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +73.41% | May 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +116.76% | May 14, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +58.96% | May 13, 2024 |
| Wedbush | Wedbush | Buy Reiterates $10 | Buy | Reiterates | $10 | +44.51% | Apr 23, 2024 |
Financial Forecast
Revenue This Year
8.01M
from 21.05M
Decreased by -61.94%
Revenue Next Year
3.36M
from 8.01M
Decreased by -58.01%
EPS This Year
-1.24
from -1.36
EPS Next Year
-1.37
from -1.24
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.4M | 10.5M | 18.6M | 71.7M | 153.4M |
| Avg | 8.0M | 3.4M | 5.3M | 28.4M | 67.4M |
| Low | 2.4M | n/a | n/a | n/a | 7.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -22.2% | 31.1% | 451.9% | 1,245.4% | 440.8% |
| Avg | -61.9% | -58.0% | 58.4% | 432.3% | 137.8% |
| Low | -88.6% | - | - | - | -74.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.07 | -1.14 | -1.17 | -0.76 | -0.27 |
| Avg | -1.24 | -1.37 | -1.43 | -1.25 | -1.23 |
| Low | -1.42 | -1.62 | -1.76 | -2.06 | -2.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.